Literature DB >> 18212099

Combination echinocandin-polyene treatment of murine mucormycosis.

Ashraf S Ibrahim1, Teclegiorgis Gebremariam, Yue Fu, John E Edwards, Brad Spellberg.   

Abstract

We previously found that caspofungin synergized with amphotericin B lipid complex in treating murine mucormycosis. We now report a similarly enhanced activity of liposomal amphotericin combined with micafungin or anidulafungin in mice with disseminated mucormycosis. The efficacy of combination echinocandin-polyene therapy for mucormycosis is a class effect.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18212099      PMCID： PMC2292548          DOI： 10.1128/AAC.01458-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.

Authors:  M Del Poeta; W A Schell; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice.

Authors:  Russell E Lewis; Georgios Chamilos; Randall A Prince; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

3.  Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

4.  Deferiprone iron chelation as a novel therapy for experimental mucormycosis.

Authors:  Ashraf S Ibrahim; John E Edwards; Yue Fu; Brad Spellberg
Journal:  J Antimicrob Chemother       Date:  2006-08-23       Impact factor: 5.790

5.  Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.

Authors:  Brad Spellberg; Yue Fu; John E Edwards; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Authors:  Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells.

Authors:  Keiichi Kinoshita; Hiromichi Iwasaki; Hiroyasu Uzui; Takanori Ueda
Journal:  Transl Res       Date:  2006-10       Impact factor: 7.012

8.  Optimization of a myeloid cell transfusion strategy for infected neutropenic hosts.

Authors:  Brad J Spellberg; Mary Collins; Valentina Avanesian; Mayela Gomez; John E Edwards; Christopher Cogle; David Applebaum; Yue Fu; Ashraf S Ibrahim
Journal:  J Leukoc Biol       Date:  2006-12-08       Impact factor: 4.962

9.  Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae.

Authors:  Ashraf S Ibrahim; Valentina Avanessian; Brad Spellberg; John E Edwards
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebermariam; Yue Fu; Lin Lin; Mohamed I Husseiny; Samuel W French; Julie Schwartz; Christopher D Skory; John E Edwards; Brad J Spellberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
  10 in total
  46 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

Review 2.  Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Authors:  Clifford Quan; Brad Spellberg
Journal:  Proc Am Thorac Soc       Date:  2010-05

3.  In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes.

Authors:  Eric Dannaoui; Patrick Schwarz; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

4.  Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.

Authors:  Guanpingsheng Luo; Teclegiorgis Gebremariam; Hongkyu Lee; Samuel W French; Nathan P Wiederhold; Thomas F Patterson; Scott G Filler; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

5.  The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis.

Authors:  A Busca; G Limerutti; F Locatelli; A Barbui; F G De Rosa; M Falda
Journal:  Infection       Date:  2011-07-07       Impact factor: 3.553

6.  Drug combinations against Mucor irregularis in vitro.

Authors:  Shuzhen Zhang; Ruoyu Li; Jin Yu
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

7.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

8.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

9.  Recent advances in the treatment of mucormycosis.

Authors:  Brad Spellberg; Ashraf S Ibrahim
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

10.  Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Mingfu Liu; Georgios Chamilos; Dimitrios Kontoyiannis; Richard Mink; Kyung J Kwon-Chung; Yue Fu; Christopher D Skory; John E Edwards; Brad Spellberg
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.